Company Description
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.
The company also provides solutions for spinal cord stimulation, radio frequency and brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
The company also focuses on applications of its technology associated with artificial intelligence. It has partnership with RBC Medical Innovations to develop a radio frequency ablation generator.
NeuroOne Medical Technologies Corporation is based in Eden Prairie, Minnesota.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 17 |
| CEO | David Rosa |
Contact Details
Address: 7599 Anagram Drive Eden Prairie, Minnesota 55344 United States | |
| Phone | 952 426 1383 |
| Website | n1mtc.com |
Stock Details
| Ticker Symbol | NMTC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001500198 |
| CUSIP Number | 64130M209 |
| ISIN Number | US64130M2098 |
| Employer ID | 27-0863354 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David A. Rosa M.D. | President, Chief Executive Officer and Director |
| Ronald W. McClurg | Chief Financial Officer |
| Steven Mertens | Chief Technology Officer |
| Mark Christianson | Co-Founder, Business Development Director and Medical Sales Liaison |
| Christopher R. Volker CFA | Chief Operating Officer |
| Hijaz Haris | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 20, 2025 | 8-K/A | [Amend] Current report |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 10-Q | Quarterly Report |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 4, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | 8-K | Current Report |